<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>pharmacology and therapeutics</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>pharmacology and therapeutics | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Refining the impact of genetic evidence on clinical success
Authors: Minikel, E. V.; Painter, J. L.; Dong, C. C.; Nelson, M. R.
Score: 49.1, Published: 2023-06-29 DOI: 10.1101/2023.06.23.23291765
The cost of drug discovery and development is driven primarily by failure, with just [~]10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="pharmacology and therapeutics" />
<meta property="og:description" content="Refining the impact of genetic evidence on clinical success
Authors: Minikel, E. V.; Painter, J. L.; Dong, C. C.; Nelson, M. R.
Score: 49.1, Published: 2023-06-29 DOI: 10.1101/2023.06.23.23291765
The cost of drug discovery and development is driven primarily by failure, with just [~]10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-07-12T10:41:10+00:00" />
<meta property="article:modified_time" content="2023-07-12T10:41:10+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="pharmacology and therapeutics"/>
<meta name="twitter:description" content="Refining the impact of genetic evidence on clinical success
Authors: Minikel, E. V.; Painter, J. L.; Dong, C. C.; Nelson, M. R.
Score: 49.1, Published: 2023-06-29 DOI: 10.1101/2023.06.23.23291765
The cost of drug discovery and development is driven primarily by failure, with just [~]10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "pharmacology and therapeutics",
      "item": "https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "pharmacology and therapeutics",
  "name": "pharmacology and therapeutics",
  "description": "Refining the impact of genetic evidence on clinical success\nAuthors: Minikel, E. V.; Painter, J. L.; Dong, C. C.; Nelson, M. R.\nScore: 49.1, Published: 2023-06-29 DOI: 10.1101/2023.06.23.23291765\nThe cost of drug discovery and development is driven primarily by failure, with just [~]10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure.",
  "keywords": [
    
  ],
  "articleBody": " Refining the impact of genetic evidence on clinical success\nAuthors: Minikel, E. V.; Painter, J. L.; Dong, C. C.; Nelson, M. R.\nScore: 49.1, Published: 2023-06-29 DOI: 10.1101/2023.06.23.23291765\nThe cost of drug discovery and development is driven primarily by failure, with just [~]10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure. Relative success (RS) between drug mechanisms with genetic support and those without varies significantly among therapy areas and development phases and improves with increasing confidence in the causal gene. RS is largely unaffected by genetic effect size, minor allele frequency, or year of discovery. Our findings suggest that we are far from reaching peak genetic insights to aid the discovery of targets for more effective drug therapies.\nNicotine reduces discrimination between threat and safety in the hippocampus, nucleus accumbens and amygdala\nAuthors: Mueller, M.; Fadai, T.; Rauh, J.; Haaker, J.\nScore: 2.1, Published: 2023-07-04 DOI: 10.1101/2023.05.08.23289647\nBackgroundNicotine intake by cigarettes is linked to the maintenance and development of anxiety disorders and impairs adaptive discrimination of threat and safety in humans. Yet, it is unclear if nicotine exerts a causal pharmacological effect on the affective and neural mechanisms that underlie aversive learning. MethodsWe conducted a pre-registered, pseudo-randomly and double-blinded pharmacological fMRI study to investigate the effect of acute nicotine on Fear Acquisition and Extinction in non-smokers (n=88). Participants were pseudo-randomly and double-blinded assigned to one of three experimental groups: 1. nicotine administration before Fear Acquisition, 2. nicotine administration before Extinction training or 3. placebo control group. ResultsOur results show that nicotine administration led to decreased discrimination between threat and safety in subjective fear. Nicotine furthermore decreased differential (threat vs. safety) activation in the hippocampus, which was functionally coupled with Nucleus Accumbens and amygdala, compared to placebo controls. Additionally, nicotine led to overactivation of the ventral tegmental area. ConclusionsThis study provides mechanistic evidence for impaired discrimination between threat and safety by the acute intake of Nicotine in non-smoking individuals. Nicotine intake directly impairs neural substrate of adaptive aversive learning and might therefore constitute a profound risk factor for the development of pathological anxiety. This study was preregistered at the German Clinical Trials Register (Deutsches Register Klinischer Studien (DRKS); https://drks.de/search/en/trial/DRKS00025233; DRKS-ID: DRKS00025233).\n",
  "wordCount" : "399",
  "inLanguage": "en",
  "datePublished": "2023-07-12T10:41:10Z",
  "dateModified": "2023-07-12T10:41:10Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/pharmacology-and-therapeutics/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      pharmacology and therapeutics
    </h1>
    <div class="post-meta"><span>updated on July 12, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.06.23.23291765">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.06.23.23291765" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.06.23.23291765">
        <p class="paperTitle">Refining the impact of genetic evidence on clinical success</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.06.23.23291765" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.06.23.23291765" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Minikel, E. V.; Painter, J. L.; Dong, C. C.; Nelson, M. R.</p>
        <p class="info">Score: 49.1, Published: 2023-06-29 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.06.23.23291765' target='https://doi.org/10.1101/2023.06.23.23291765'> 10.1101/2023.06.23.23291765</a></p>
        <p class="abstract">The cost of drug discovery and development is driven primarily by failure, with just [~]10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure. Relative success (RS) between drug mechanisms with genetic support and those without varies significantly among therapy areas and development phases and improves with increasing confidence in the causal gene. RS is largely unaffected by genetic effect size, minor allele frequency, or year of discovery. Our findings suggest that we are far from reaching peak genetic insights to aid the discovery of targets for more effective drug therapies.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.05.08.23289647">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.05.08.23289647" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.05.08.23289647">
        <p class="paperTitle">Nicotine reduces discrimination between threat and safety in the hippocampus, nucleus accumbens and amygdala</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.05.08.23289647" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.05.08.23289647" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Mueller, M.; Fadai, T.; Rauh, J.; Haaker, J.</p>
        <p class="info">Score: 2.1, Published: 2023-07-04 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.05.08.23289647' target='https://doi.org/10.1101/2023.05.08.23289647'> 10.1101/2023.05.08.23289647</a></p>
        <p class="abstract">BackgroundNicotine intake by cigarettes is linked to the maintenance and development of anxiety disorders and impairs adaptive discrimination of threat and safety in humans. Yet, it is unclear if nicotine exerts a causal pharmacological effect on the affective and neural mechanisms that underlie aversive learning.

MethodsWe conducted a pre-registered, pseudo-randomly and double-blinded pharmacological fMRI study to investigate the effect of acute nicotine on Fear Acquisition and Extinction in non-smokers (n=88). Participants were pseudo-randomly and double-blinded assigned to one of three experimental groups:

1. nicotine administration before Fear Acquisition, 2. nicotine administration before Extinction training or 3. placebo control group.

ResultsOur results show that nicotine administration led to decreased discrimination between threat and safety in subjective fear. Nicotine furthermore decreased differential (threat vs. safety) activation in the hippocampus, which was functionally coupled with Nucleus Accumbens and amygdala, compared to placebo controls. Additionally, nicotine led to overactivation of the ventral tegmental area.

ConclusionsThis study provides mechanistic evidence for impaired discrimination between threat and safety by the acute intake of Nicotine in non-smoking individuals. Nicotine intake directly impairs neural substrate of adaptive aversive learning and might therefore constitute a profound risk factor for the development of pathological anxiety.

This study was preregistered at the German Clinical Trials Register (Deutsches Register Klinischer Studien (DRKS); https://drks.de/search/en/trial/DRKS00025233; DRKS-ID: DRKS00025233).</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
